Loading…
Amrutanjan Health Care (AMRUTANJAN)₹519.85+0.40%Pharmaceuticals
In the Mar 2026 quarter (standalone), Amrutanjan Health Care reported sales of ₹150 Cr, up 11.0% from Mar 2025, and net profit of ₹16.02 Cr, up 6.6% year on year. For the year to Mar 2026, sales were ₹503 Cr and net profit ₹58.06 Cr.
Company filings, standalone accounts; latest reported quarter Mar 2026
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 77.97 | 99.03 | 117 | 127 | 84.01 | 110 | 123 | 135 | 94.04 | 118 | 141 | 150 |
| Expenses | 70.84 | 91.70 | 94.75 | 111 | 79.74 | 95.75 | 98.75 | 118 | 85.68 | 101 | 116 | 124 |
| Operating Profit | 7.02 | 7.02 | 22.07 | 16.04 | 4.01 | 14.03 | 23.05 | 18.04 | 8.02 | 17.04 | 25.09 | 26.06 |
| OPM % | 9.0% | 7.0% | 18.0% | 13.0% | 4.2% | 12.0% | 19.0% | 12.9% | 9.0% | 14.0% | 18.0% | 16.9% |
| Other Income | 4.01 | 4.01 | 4.01 | 5.01 | 4.01 | 4.01 | 4.01 | 5.01 | 4.01 | 4.01 | 3.01 | −3.01 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.99 | 1.99 | 1.99 | 1.99 | 2.01 | 1.99 | 1.99 | 1.99 | 1.99 | 1.99 | 1.99 | 2.01 |
| Profit before tax | 9.01 | 9.01 | 24.01 | 20.01 | 6.01 | 16.02 | 26.03 | 21.01 | 11.01 | 18.99 | 25.99 | 21.02 |
| Tax % | 26.0% | 26.0% | 26.0% | 30.0% | 27.0% | 26.0% | 26.0% | 27.0% | 26.0% | 27.0% | 26.0% | 23.0% |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | −0.91 | −5.85 |
| Net Profit | 7.01 | 7.01 | 17.03 | 14.02 | 5.01 | 12.02 | 19.02 | 15.03 | 8.02 | 14.01 | 19.03 | 16.02 |
| EPS (Rs) | 2.39 | 2.36 | 6.02 | 4.71 | 1.59 | 4.07 | 6.64 | 5.24 | 2.86 | 4.82 | 6.72 | 5.59 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 174 | 207 | 220 | 253 | 261 | 333 | 406 | 380 | 421 | 452 | 503 | 503 |
| Expenses | 143 | 178 | 191 | 221 | 230 | 257 | 325 | 334 | 368 | 393 | 426 | 426 |
| Operating Profit | 32.07 | 29.10 | 28.07 | 31.10 | 31.06 | 75.17 | 80.25 | 45.10 | 52.12 | 58.14 | 76.19 | 76.21 |
| OPM % | 18.0% | 14.0% | 13.0% | 12.0% | 11.9% | 22.0% | 20.0% | 12.0% | 12.0% | 12.9% | 14.9% | 15.2% |
| Other Income | 6.01 | 7.01 | 8.01 | 7.01 | 8.02 | 11.01 | 15.03 | 15.03 | 16.02 | 18.03 | 9.02 | 8.02 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.01 | 1.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 3.01 | 1.99 | 3.01 | 2.99 | 3.99 | 3.99 | 3.99 | 4.99 | 5.99 | 6.99 | 6.01 | 7.98 |
| Profit before tax | 35.03 | 34.01 | 33.01 | 35.03 | 34.04 | 82.07 | 91.04 | 54.03 | 62.03 | 69.04 | 78.07 | 77.01 |
| Tax % | 35.0% | 35.0% | 39.0% | 29.0% | 27.0% | 25.0% | 26.0% | 26.0% | 27.0% | 26.0% | 26.0% | — |
| Exceptional items | 0.99 | 0.00 | 0.99 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | −6.99 | −6.76 |
| Net Profit | 22.05 | 22.05 | 20.04 | 25.06 | 25.04 | 61.07 | 67.14 | 40.05 | 45.06 | 51.09 | 58.06 | 57.08 |
| EPS (Rs) | 7.66 | 7.45 | 6.83 | 8.37 | 8.56 | 20.87 | 22.92 | 13.60 | 15.52 | 17.53 | 19.98 | 19.99 |
| Dividend payout % | 25.1% | 26.1% | 22.1% | 26.0% | 24.0% | 20.1% | 20.1% | 34.1% | 30.1% | 26.1% | 24.1% | — |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 |
| Reserves | 102 | 118 | 113 | 126 | 143 | 156 | 213 | 262 | 288 | 286 | 324 | 367 |
| Borrowings | 0.00 | 0.00 | 2.01 | 0.00 | 0.00 | 2.01 | 1.01 | 1.01 | 0.99 | 2.01 | 2.01 | 2.01 |
| Other Liabilities | 24.91 | 28.08 | 33.90 | 38.06 | 41.87 | 43.92 | 56.89 | 83.84 | 69.91 | 76.99 | 92.55 | 137 |
| Total Liabilities | 130 | 149 | 152 | 166 | 188 | 205 | 274 | 350 | 362 | 367 | 421 | 509 |
| Fixed Assets | 13.04 | 22.06 | 27.06 | 28.09 | 26.06 | 26.08 | 23.05 | 28.10 | 49.11 | 50.11 | 49.11 | 51.13 |
| CWIP | 3.99 | 0.99 | 0.99 | 0.00 | 0.00 | 0.00 | 1.99 | 16.96 | 0.99 | 1.99 | 15.97 | 105 |
| Investments | 14.03 | 10.04 | 10.03 | 8.02 | 18.05 | 18.06 | 18.05 | 13.03 | 5.01 | 0.00 | 0.00 | 3.01 |
| Other Assets | 99.89 | 116 | 115 | 131 | 144 | 161 | 232 | 291 | 307 | 315 | 356 | 349 |
| Inventories | 7.01 | 8.02 | 10.02 | 10.03 | 15.03 | 24.05 | 17.03 | 26.06 | 29.08 | 29.08 | 27.06 | 37.10 |
| Trade receivables | 25.94 | 25.96 | 28.93 | 27.94 | 32.93 | 25.95 | 17.95 | 37.92 | 32.91 | 47.90 | 55.84 | 60.86 |
| Cash & equivalents | 37.91 | 47.87 | 30.88 | 72.81 | 80.81 | 35.88 | 139 | 87.71 | 69.81 | 26.92 | 82.81 | 32.91 |
| Total Assets | 130 | 149 | 152 | 166 | 188 | 205 | 274 | 350 | 362 | 367 | 421 | 509 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | 18.94 | 20.95 | 7.97 | 18.95 | 20.95 | 17.94 | 90.77 | 51.85 | 19.95 | 27.91 | 50.90 | 35.92 |
| Cash from investing activity | −4.98 | 0.99 | 0.00 | −7.97 | −10.96 | −13.96 | −87.70 | −35.87 | −1.99 | 18.94 | −30.89 | −20.94 |
| Cash from financing activity | −12.04 | −11.03 | −5.02 | −9.03 | −7.03 | −12.04 | −7.03 | −17.06 | −15.06 | −48.17 | −13.05 | −14.05 |
| Net cash flow | 1.99 | 11.99 | 2.99 | 1.99 | 2.99 | −7.01 | −3.99 | −1.01 | 2.99 | −0.99 | 6.01 | 0.99 |
| Capex | 6.01 | 2.01 | 4.01 | 2.99 | 2.01 | 3.01 | 2.01 | 23.02 | 9.01 | 7.01 | 36.01 | 55.01 |
| Free cash flow | 12.98 | 19.97 | 4.99 | 17.97 | 18.95 | 15.96 | 88.85 | 28.96 | 10.98 | 20.94 | 14.97 | −18.96 |
| CFO / OP % | 114.0% | 104.0% | 77.0% | 105.0% | 101.0% | 95.0% | 146.0% | 96.0% | 81.0% | 86.0% | 118.0% | 73.0% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 61 | 54 | 50 | 45 | 46 | 36 | 18 | 33 | 31 | 41 | 44 | 43 |
| Inventory days | 45 | 45 | 45 | 41 | 46 | 75 | 46 | 54 | 59 | 51 | 46 | 57 |
| Days payable | 47 | 52 | 111 | 103 | 93 | 99 | 107 | 123 | 96 | 97 | 114 | 107 |
| Cash conversion cycle | 61 | 48 | −15 | −16 | 0 | 13 | −41 | −35 | −6 | −5 | −23 | −6 |
| Working capital days | 43 | 46 | 77 | 27 | 31 | 71 | 29 | 93 | 118 | 174 | 100 | 97 |
| ROCE % | 26.0% | 29.0% | 28.0% | 25.0% | 25.0% | 23.0% | 44.0% | 38.0% | 19.0% | 21.0% | 22.0% | 25.0% |
For the Mar 2026 quarter, Amrutanjan Health Care reported sales of ₹150 Cr, up 11.0% year on year and net profit of ₹16.02 Cr, up 6.6% year on year. The operating margin was 16.9%.
Amrutanjan Health Care's sales for the year to Mar 2026 were ₹503 Cr; over the last twelve months they were ₹503 Cr.
Net profit for the year to Mar 2026 was ₹58.06 Cr, and ₹57.08 Cr over the last twelve months. Earnings per share over the same trailing period were ₹19.99.
Amrutanjan Health Care reported borrowings of ₹2.01 Cr at Mar 2026, against cash and equivalents of ₹32.91 Cr.
Cash from operations was ₹35.92 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹18.96 Cr.